Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | AC Dietz, SA. Grupp, TW Laetsch, H Stefanski, GD Myers, H Bittencourt, J Buechner, ER. Nemecek, PL. Martin, H Hiramatsu, F Mechinaud, GA. Yanik, B De Moerloose, PAnn Wood, L Rasouliyan, Y Zhang, SK. Thomas, S Shah, A Harris | ||||||||||||
Title | Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL). | ||||||||||||
|
|||||||||||||
URL | http://abstracts.asco.org/199/AbstView_199_187018.html | ||||||||||||
Abstract Text | J Clin Oncol 35, 2017 (suppl; abstr 10523) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Tisagenlecleucel | Tisagenlecleucel | 0 | 15 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tisagenlecleucel | Kymriah | CTL019 | Kymriah (tisagenlecleucel) is a preparation of autologous T-lymphocytes engineered to express chimeric antigen receptors targeting CD19-positive cells, resulting in anti-tumor immune response (J Clin Oncol 35, 2017 (suppl; abstr 10523)). Kymriah (tisagenlecleucel) is FDA approved for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia, adult patient with relapsed or refractory large B-cell lymphoma, and adult patients with relapsed or refractory follicular lymphoma (FDA.gov). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|